FR2792531B1 - USE OF DEFECTIVE RECOMBINANT ADENOVIRUS COMPRISING A NUCLEIC ACID ENCODING AN ANGIOGENIC FACTOR FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION - Google Patents

USE OF DEFECTIVE RECOMBINANT ADENOVIRUS COMPRISING A NUCLEIC ACID ENCODING AN ANGIOGENIC FACTOR FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

Info

Publication number
FR2792531B1
FR2792531B1 FR9905272A FR9905272A FR2792531B1 FR 2792531 B1 FR2792531 B1 FR 2792531B1 FR 9905272 A FR9905272 A FR 9905272A FR 9905272 A FR9905272 A FR 9905272A FR 2792531 B1 FR2792531 B1 FR 2792531B1
Authority
FR
France
Prior art keywords
treatment
nucleic acid
acid encoding
recombinant adenovirus
arterial hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9905272A
Other languages
French (fr)
Other versions
FR2792531A1 (en
Inventor
Serge Adnot
Didier Branellec
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9905272A priority Critical patent/FR2792531B1/en
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to MXPA01010849A priority patent/MXPA01010849A/en
Priority to KR1020017013633A priority patent/KR20020001846A/en
Priority to JP2000614380A priority patent/JP2002543097A/en
Priority to CA002370404A priority patent/CA2370404A1/en
Priority to CZ20013813A priority patent/CZ20013813A3/en
Priority to AU43017/00A priority patent/AU782833B2/en
Priority to CN00806521A priority patent/CN1376197A/en
Priority to EP00922713A priority patent/EP1173564A1/en
Priority to PL00351114A priority patent/PL351114A1/en
Priority to NZ515233A priority patent/NZ515233A/en
Priority to BR0010034-0A priority patent/BR0010034A/en
Priority to PCT/FR2000/001060 priority patent/WO2000065043A1/en
Priority to HU0200961A priority patent/HUP0200961A3/en
Priority to SI200020023A priority patent/SI20750A/en
Priority to IL14583400A priority patent/IL145834A0/en
Publication of FR2792531A1 publication Critical patent/FR2792531A1/en
Priority to NO20015223A priority patent/NO20015223D0/en
Priority to US09/983,885 priority patent/US20020086004A1/en
Publication of FR2792531B1 publication Critical patent/FR2792531B1/en
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • C07K14/501—Fibroblast growth factors [FGF] acidic FGF [aFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
FR9905272A 1999-04-26 1999-04-26 USE OF DEFECTIVE RECOMBINANT ADENOVIRUS COMPRISING A NUCLEIC ACID ENCODING AN ANGIOGENIC FACTOR FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION Expired - Lifetime FR2792531B1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR9905272A FR2792531B1 (en) 1999-04-26 1999-04-26 USE OF DEFECTIVE RECOMBINANT ADENOVIRUS COMPRISING A NUCLEIC ACID ENCODING AN ANGIOGENIC FACTOR FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
PCT/FR2000/001060 WO2000065043A1 (en) 1999-04-26 2000-04-21 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
KR1020017013633A KR20020001846A (en) 1999-04-26 2000-04-21 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
CA002370404A CA2370404A1 (en) 1999-04-26 2000-04-21 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
CZ20013813A CZ20013813A3 (en) 1999-04-26 2000-04-21 Use of defective recombinant adenovirus vector containing nucleic acid encoding angiogenic factor for preparing a medicament intended for treating lung hypertension
AU43017/00A AU782833B2 (en) 1999-04-26 2000-04-21 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
CN00806521A CN1376197A (en) 1999-04-26 2000-04-21 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
EP00922713A EP1173564A1 (en) 1999-04-26 2000-04-21 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
HU0200961A HUP0200961A3 (en) 1999-04-26 2000-04-21 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
NZ515233A NZ515233A (en) 1999-04-26 2000-04-21 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
MXPA01010849A MXPA01010849A (en) 1999-04-26 2000-04-21 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension.
JP2000614380A JP2002543097A (en) 1999-04-26 2000-04-21 Use of a recombinant defective adenovirus containing nucleic acid encoding a pro-angiogenic factor to treat pulmonary arterial hypertension
PL00351114A PL351114A1 (en) 1999-04-26 2000-04-21 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
SI200020023A SI20750A (en) 1999-04-26 2000-04-21 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
IL14583400A IL145834A0 (en) 1999-04-26 2000-04-21 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
BR0010034-0A BR0010034A (en) 1999-04-26 2000-04-21 Use of a vector, preparation of a drug useful for the prevention, improvement and / or treatment of pulmonary arterial hypertension, and pharmaceutical composition
NO20015223A NO20015223D0 (en) 1999-04-26 2001-10-25 Use of defective recombinant adenoviruses containing a nucleic acid encoding an angiogenic factor for the treatment of pulmonary arterial hypertension
US09/983,885 US20020086004A1 (en) 1999-04-26 2001-10-26 Use of a defective recombinant adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9905272A FR2792531B1 (en) 1999-04-26 1999-04-26 USE OF DEFECTIVE RECOMBINANT ADENOVIRUS COMPRISING A NUCLEIC ACID ENCODING AN ANGIOGENIC FACTOR FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

Publications (2)

Publication Number Publication Date
FR2792531A1 FR2792531A1 (en) 2000-10-27
FR2792531B1 true FR2792531B1 (en) 2003-01-31

Family

ID=9544871

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9905272A Expired - Lifetime FR2792531B1 (en) 1999-04-26 1999-04-26 USE OF DEFECTIVE RECOMBINANT ADENOVIRUS COMPRISING A NUCLEIC ACID ENCODING AN ANGIOGENIC FACTOR FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

Country Status (1)

Country Link
FR (1) FR2792531B1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717495B1 (en) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
WO1997030155A1 (en) * 1996-02-15 1997-08-21 Chiron Corporation Gene therapy method using fgf-5
JP2001503755A (en) * 1996-11-01 2001-03-21 ユーロジーン・リミテッド Therapeutic use and delivery device for agents that stimulate NO or prostacyclin production
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression

Also Published As

Publication number Publication date
FR2792531A1 (en) 2000-10-27

Similar Documents

Publication Publication Date Title
FR14C0010I2 (en) USE OF (Z)-2-CYANO-3-HYDROXY-BUT-2-ENOIC-(4'-TRIFLUOROMETHYLPHENYL)-AMIDE ACID FOR THE TREATMENT OF MULTIPLE SCLEROSIS
DZ3177A1 (en) Copolymer comprising isophthalic acid
DE69733249T8 (en) DETERMINATION OF THE EXACT POSITION OF ENDOSCOPES
DE69802295T2 (en) SIDE IDENTIFICATION BY DETERMINING OPTICAL PROPERTIES
DE3784366D1 (en) REINFORCING FIBER FOR CEMENT.
DE69839263D1 (en) HEMOGLOBIN MUTANTS WITH LIQUID NITROGEN OXIDE REMOVAL CAPACITY
DZ3014A1 (en) Medicines for the treatment of hypertension.
FR2792531B1 (en) USE OF DEFECTIVE RECOMBINANT ADENOVIRUS COMPRISING A NUCLEIC ACID ENCODING AN ANGIOGENIC FACTOR FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
NO20015223D0 (en) Use of defective recombinant adenoviruses containing a nucleic acid encoding an angiogenic factor for the treatment of pulmonary arterial hypertension
DE69714568T2 (en) Procedure for determining a blood factor
FR2767324B1 (en) USE OF RECOMBINANT ENVELOPE PROTEINS FOR THE DIAGNOSIS OF DENGUE VIRUS
FR2717499B1 (en) Fragments of recombinant antibodies synthesized and biotinylated in E. coli, their use in immunoassays and in purification by immunoaffinity.
FR2741535B1 (en) NEW PREPARATIONS FOR THE BUCCO-PHARYNGEE SPHERE
NO954147D0 (en) Improvements regarding patient lifts
FR2743948B1 (en) SHEATH, ESPECIALLY FOR HOSPITAL ESTABLISHMENT
DE9403654U1 (en) Pouring beak
FR2748753B1 (en) NEW ADENOVIRAL VECTORS FOR GENE THERAPY
FR2754527B1 (en) APPARATUS FOR MOVING A LOAD IN A BALANCED CONDITION
NO963559L (en) Recombinant adenoviruses encoding brain-derived naurotrophic factor (BDNF)
FR2760374B1 (en) REMOVABLE SPATULA FOR SNOWSHOES
FR2772270B1 (en) USE OF AN ESTROGEN FOR THE TREATMENT OF POSTNATAL DEPRESSION
FR2720391B1 (en) Molten abrasive based on aluminum oxynitride.
FR2748510B1 (en) ANGLE SUPPORT FOR SCAFFOLDING
FR2791999B1 (en) COMPOSITION FOR THE CONSERVATION OF INFECTIOUS RECOMBINANT ADENOVIRUSES
FR2768754B1 (en) SELF-SUPPORTING CORNICE FOR ARTWORK

Legal Events

Date Code Title Description
CD Change of name or company name